Introduction: Your PRP at Clinic A Is Not Your PRP at Clinic B

PRP looks like a single product. It is not. Two clinics can both market "PRP injection" or "PRP facial" or "PRP scalp microinjection" and the patient can receive products that differ by a factor of five to ten in actual platelet concentration, by an order of magnitude in leukocyte content, and by entirely different preparation methods that produce entirely different clinical performance.

The cluster has multiple existing PRP articles — including ours — that describe what PRP does, why patients use it, what conditions it treats, what the experience is like, and what the costs are. All useful. None of them answer the question that determines whether the PRP you receive will actually deliver the outcome you are paying for: what is actually in your tube?

This 2026 patient-protection guide is the autologous-product transparency layer of the verification trilogy. The first piece, "Exosome Therapy in Colombia — What's Actually in That Vial?", addresses allogeneic product transparency. The second piece, "Volume Beats Credentials", addresses procedural infrastructure verification. PRP is the third leg — the autologous product that looks like a single thing and isn't.

If you have been told "we'll do PRP," that is not yet a clinical specification. It is the start of one. The bedside questions in this article complete it.

The PRP Variability Spectrum

In the PRP literature, "PRP" can refer to preparations with platelet concentrations ranging from approximately 1.5× whole blood baseline at the low end to 5–9× at the high end. The whole blood baseline platelet count for a typical adult is roughly 150,000–400,000 platelets per microliter. A 1.5× preparation delivers roughly 250,000–600,000 platelets per microliter. A 5–9× preparation delivers roughly 1,000,000–3,500,000 platelets per microliter.

These are not the same product clinically. A growing body of evidence suggests that for most regenerative indications, platelet concentrations in the 3–5× range produce the most consistent clinical effect, with diminishing or even negative returns above and below this range for certain indications. A 1.5× preparation may be insufficient. A 9× preparation may be excessive for some indications and underwhelming relative to its cost.

The clinical performance of the product depends on the platelet concentration delivered, the leukocyte content (more on this in the next section), the preparation system used, and the spin protocol applied. None of these are visible to the patient. All of them should be documented.

Single-Spin vs Double-Spin Preparation: What Each Produces

PRP preparation centers on density-gradient centrifugation of anticoagulated whole blood. Two general protocols dominate clinical practice:

Single-spin protocols (also called "soft-spin" PRP) apply one centrifugation step at a relatively lower speed for a longer duration. The result is plasma fraction enriched in platelets, with a typical concentration in the 1.5× to 3× range and a relatively higher residual leukocyte content. Single-spin protocols tend to recover a higher percentage of total platelets from the original blood draw (yield in the 60–80% range) at lower concentrations.

Double-spin protocols (also called "hard-spin" PRP) apply two sequential centrifugation steps. The first separates plasma from red blood cells; the second concentrates the platelets within the plasma fraction. The result is plasma with a typical concentration in the 3× to 9× range and lower residual leukocyte content. Double-spin protocols tend to recover a lower percentage of total platelets (yield in the 30–60% range) at higher concentrations.

Neither is universally superior. Higher concentration is not the same as better outcome. The right protocol depends on the indication and the system used.

Leukocyte-Rich (LR-PRP) vs Leukocyte-Poor (LP-PRP): When Each Is Appropriate

The white blood cell content of the final PRP product is one of the most clinically meaningful variables and one of the most poorly disclosed. Leukocytes (especially neutrophils) carry inflammatory mediators. Their inclusion or exclusion in the final product affects the clinical performance.

Leukocyte-rich PRP (LR-PRP) retains a substantial proportion of the leukocytes from the original blood draw. The inflammatory mediators in LR-PRP are sometimes considered beneficial for indications where a controlled inflammatory response supports tissue remodeling — particularly some tendinopathy indications.

Leukocyte-poor PRP (LP-PRP) is processed to remove or substantially reduce the leukocyte fraction. LP-PRP delivers the platelet-derived growth factor signal without the leukocyte-driven inflammatory burst.

Indication-Appropriate Selection (Per Current Evidence)

Facial aesthetic (skin rejuvenation, vampire facial, vampire facelift, undereye): LP-PRP generally preferred. The lower inflammatory profile reduces post-procedure erythema, swelling, and post-inflammatory hyperpigmentation risk — particularly important for Fitzpatrick IV–VI skin types where post-inflammatory hyperpigmentation is a meaningful clinical concern.
Scalp microinjection for hair restoration: LP-PRP generally preferred. Lower scalp inflammation, better tolerability for the typical 3–6 session series.
Intra-articular knee injection (osteoarthritis): LP-PRP generally preferred per recent meta-analyses. The lower neutrophil burden in the joint space appears to correlate with better symptomatic outcomes for OA.
Tendinopathy (lateral epicondylitis, Achilles, patellar): LR-PRP often preferred per much of the published literature, though the evidence is mixed and indication-specific. The controlled inflammatory response may support tissue remodeling.
Wound healing and post-surgical recovery: Variable; selection depends on the specific application.
Sexual wellness (P-Shot, O-Shot): LP-PRP generally preferred for tolerability.

A clinic that uses the same LR or LP product for every indication is not selecting per indication. A serious practice selects per indication and can explain why.

The Major Commercial PRP Systems

The preparation system used determines what the patient actually receives. The major commercial systems in clinical use produce meaningfully different products. The patient has the right to ask which system is in use.

Eclipse PRP — A widely used clinical PRP kit (often single-spin, with kit-defined protocol). Typical platelet concentration in the 2–3× baseline range. Often LR depending on protocol used. Common in aesthetic and orthopedic practice.

Selphyl PRP-FM (Platelet-Rich Fibrin Matrix) — A specific system that produces PRP with a fibrin scaffold component, often used in aesthetic indications including the original "vampire facelift" protocol. Distinct product profile from standard PRP.

Magellan (Isto Biologics / formerly Arteriocyte) — A higher-concentration double-spin system. Typical platelet concentration in the 4–7× baseline range. LP profile. Used in orthopedic and aesthetic applications.

Arthrex Angel System — A widely used orthopedic PRP system. The Angel System allows operator-adjustable hematocrit and yields a relatively high-concentration product. LP-capable depending on protocol settings. Common in sports medicine and orthopedics.

Regen Lab (Regen BCT) — A widely used system with multiple kit configurations. Typical platelet concentration in the 2–4× range. Often LP. Common in aesthetic and orthopedic practice.

Harvest SmartPrep (Terumo BCT) — A double-spin system with relatively higher platelet concentrations. Used in orthopedic and surgical applications.

EmCyte Pure PRP — A double-spin system designed to deliver high-concentration LP-PRP. Typical platelet concentration in the 5–9× range. Common in orthopedic, hair restoration, and aesthetic practice.

Other systems — There are many additional systems on the market. The same questions apply to any: which system, what concentration, LR or LP, single or double spin.

The above is descriptive only and based on general manufacturer specifications and published comparative studies; the specific concentration and yield achieved depends on the operator's protocol adherence, the patient's baseline platelet count, and the clinical workflow. The important point for the patient is to ask the question. The serious clinic answers in five seconds.

Indication-by-Indication PRP System Selection

Building on the LR vs LP framework above, the practical system selection by indication:

Facial aesthetic — vampire facial (microneedling + topical PRP): LP-PRP, typically 2–4× concentration. The product is applied topically post-microneedling rather than injected, so very high concentrations are not the priority; the priority is clean preparation and adequate volume.
Facial aesthetic — vampire facelift (PRP injectable + HA filler combination): LP-PRP, typically 3–5× concentration, in combination with HA filler per the original Runels protocol.
Undereye / tear-trough PRP: LP-PRP, typically 3–4× concentration, with technique sensitivity for the periorbital area.
Scalp microinjection for hair: LP-PRP, typically 3–5× concentration, in a standardized injection density protocol.
Intra-articular knee for osteoarthritis: LP-PRP, typically 4–6× concentration per recent meta-analyses, with ultrasound or fluoroscopy guidance.
Tendinopathy (lateral epicondylitis, Achilles, patellar): LR-PRP often preferred, typically 4–6× concentration, with ultrasound guidance and structured eccentric rehabilitation protocol.
Wound healing and post-surgical recovery: Indication-specific.
Sexual wellness (P-Shot, O-Shot): LP-PRP, typically 3–5× concentration.

A clinic that does the same protocol for every indication is not selecting per indication.

Platelet Concentration Documentation: What the Patient Should Have in Their Record

A serious PRP practice documents the following per administration:

The patient's baseline platelet count (from a CBC drawn at the time of the PRP draw or within a recent window).
The volume of whole blood drawn.
The system and kit used (with kit lot number for traceability).
The spin protocol applied (single vs double, RPM, duration).
The volume of PRP product produced.
The post-preparation platelet concentration (per manual count or device-reported value).
The leukocyte content profile (LR or LP, with approximate concentration if measured).
The yield percentage (proportion of original platelets recovered in the final product).
The anticoagulant used (typically ACD-A; heparin in selected workflows).
The volume administered and the administration site(s).

This is not exotic documentation. It is standard for any serious PRP practice and takes a few minutes per case. A clinic that cannot produce this documentation is administering a product they have not characterized.

The Eight Bedside PRP Questions

These take five minutes at a serious practice. Ask all eight before the procedure.

1. Which PRP preparation system are you using today?

Acceptable answer: a specific named system (Eclipse, Selphyl, Magellan, Arthrex Angel, Regen, Harvest SmartPrep, EmCyte Pure PRP, etc.). "Just standard PRP" is not an answer.

2. Is this single-spin or double-spin protocol?

Acceptable answer: a clear specification.

3. Will this be leukocyte-rich (LR-PRP) or leukocyte-poor (LP-PRP)? Why is that the right choice for my indication?

Acceptable answer: the clinic specifies LR or LP and gives indication-specific reasoning.

4. What platelet concentration are you targeting? What was the platelet concentration of the previous patient you treated with this system today?

Acceptable answer: a specific concentration target (typically expressed in multiples of baseline or in absolute platelet count per microliter), with willingness to document.

5. What is my baseline platelet count? Did you measure it today, or are we using a recent CBC?

Acceptable answer: a specific baseline value, ideally from a CBC drawn at the time of the procedure or recent window.

6. What is the expected yield percentage with this system and protocol?

Acceptable answer: a number (typical yields range from 30% to 80% depending on system and protocol).

7. Is the preparation closed-system or open-system? What is the sterility validation?

Acceptable answer: closed-system kit specification, with documented sterility validation. Open-system preparation can be done competently but requires more rigorous technique and validation.

8. What anticoagulant are you using — ACD-A or heparin?

Acceptable answer: a specific anticoagulant, with reasoning. ACD-A is the most common and generally preferred for most indications.

Red Flags in PRP Preparation

Any one of these warrants pause and a request for clarification.

Cannot name the preparation system.
Cannot specify single-spin vs double-spin.
Cannot specify LR vs LP.
Same protocol for every indication regardless of clinical context.
No platelet concentration target or measurement.
No baseline platelet count documentation.
No yield percentage documentation.
Open-system preparation with no sterility validation framework.
Reuses kits or single-use components.
"Standard PRP" with no further specification.
Charges injectable-PRP prices for autologous serum without proper preparation (which is not actually PRP).
No CBC documentation.
Cannot explain why their selection is appropriate for the indication.

Who Is and Is NOT a Candidate for PRP

Candidates

Most adults with appropriate indications and adequate baseline platelet count.
Patients with mild orthopedic pathology (KL Grade 1–2 OA, mild tendinopathy) where PRP-first protocol is appropriate per the Cost-Per-Result buyer's framework.
Patients with facial aesthetic indications appropriate for vampire facial, vampire facelift, undereye PRP, or scalp microinjection.
Patients with hair restoration on viable miniaturizing follicles (Norwood I–IV with adequate viable follicle population).
Patients seeking post-procedure recovery acceleration (paired with microneedling, fractional laser, etc.).

NOT candidates

Active malignancy or recent malignancy (case-by-case clearance).
Active untreated infection (especially at the planned injection site).
Severe thrombocytopenia (the autologous source product would be inadequate; a clinical CBC threshold should be applied).
Bleeding disorders (von Willebrand disease, hemophilia, etc.).
Patients on therapeutic anticoagulation (warfarin, DOACs at therapeutic dose) without coordination with the prescribing physician.
Pregnancy and breastfeeding (relative contraindication, case-by-case).
Patients with sepsis, active hepatitis or HIV viremia (case-by-case clearance).
Patients with end-stage radiographic disease (KL Grade 4 OA, full-thickness tendon tear) for whom PRP alone is inadequate — see the Cost-Per-Result buyer's framework for tier-right alternatives.

How PRP Sits in the Combined-Protocol Architecture

Every plan is personalized. Message us on WhatsApp and we'll send your quote after reviewing your case.

Site-specific targeting — for orthopedic indications, intra-articular PRP delivers concentrated growth factor signal at the joint while the systemic stem cell intervention provides the broader regenerative substrate.
Tendinopathy adjunct — for selected tendinopathy indications, LR-PRP at the tendon insertion paired with systemic stem cell intervention.
Aesthetic recovery — vampire-facial-style topical PRP paired with microneedling and exosome layering for facial rejuvenation protocols.
Hair restoration — LP-PRP scalp microinjection paired with exosome adjunct on viable follicles.

For the full sequencing detail, see the Combined Peptide + Stem Cell Therapy: The Clinical Sequencing Guide (2026).

Frequently Asked Questions

1. Why does my PRP at clinic A produce a different result than my PRP at clinic B?

Almost always because the products are different — different preparation system, different spin protocol, different leukocyte profile, different platelet concentration. Same word, different products.

2. Should I require my platelet concentration documented in my record?

You should request that the baseline platelet count, system used, spin protocol, leukocyte profile, post-preparation concentration, and yield percentage be documented. A serious practice provides this as standard documentation.

3. Is higher platelet concentration always better?

No. The current evidence base suggests platelet concentrations in the 3–5× baseline range produce the most consistent clinical effect for most regenerative indications. Above or below this range, returns can diminish.

4. What is the difference between PRP and PRF (platelet-rich fibrin)?

PRF is a different product produced by a different protocol (typically without anticoagulant, with a specific spin protocol that produces a fibrin-based scaffold). PRF is used in specific dental, surgical, and aesthetic applications. The verification questions are similar but with PRF-specific specifications.

5. What is the difference between PRP and "platelet lysate" or "growth factor concentrate" (GFC)?

Different products. PRP delivers intact platelets that release growth factors at the injection site. Platelet lysate / GFC delivers pre-released growth factors directly. Different clinical performance, different indications, different verification questions.

6. Is autologous serum the same as PRP?

No. Autologous serum (the liquid that separates from clotted blood) does not contain concentrated platelets. A clinic that markets autologous serum as PRP at PRP pricing is mislabeling the product.

7. Can I bring my own PRP from a U.S. clinic?

PRP is autologous and prepared at the time of administration; bringing pre-prepared product is not standard practice and typically not appropriate.

8. How many PRP sessions do I need?

Indication-dependent. Facial aesthetic series typically 3 sessions over 6–12 weeks. Hair restoration typically 3–6 sessions over 3–6 months with maintenance. Knee OA often 3 sessions over 6–12 weeks. Tendinopathy often 1–3 sessions with structured rehabilitation.

9. How long do PRP results last?

Indication-dependent. Facial aesthetic results typically 6–12 months. Hair restoration requires periodic maintenance microinjection. Orthopedic results 6–12 months for many patients with mild indications, often shorter for moderate-severe pathology where PRP alone is undertier.

10. Can I do PRP if I am on TRT, GLP-1, or HRT?

Generally yes, with no specific contraindication for these therapies.

11. What is ACD-A and why does it matter?

Anticoagulant Citrate Dextrose Solution-A is the most common anticoagulant used in PRP preparation. It preserves platelet function while preventing clotting during processing. Heparin can be used in some workflows but is not preferred for most PRP applications.

12. Should I have a CBC drawn before my PRP procedure?

Yes. A baseline platelet count is the reference for documenting the post-preparation concentration and the yield percentage. A serious practice draws or obtains a CBC at or near the time of the procedure.

Cross-Linked Companion Guides

Exosome Therapy in Colombia — What's Actually in That Vial? (2026) — first leg of the verification trilogy (allogeneic product transparency).
Volume Beats Credentials: The 2026 Stem Cell Clinic Verification Framework Beyond Credentials (2026) — second leg of the verification trilogy (procedural infrastructure).
Cost-Per-Result: When PRP Beats Exosomes Beats Stem Cells in Medellín (2026) — for the buyer's economic decision framework that informs when PRP is the tier-right modality.
Combined Peptide + Stem Cell Therapy: The Clinical Sequencing Guide (2026) — for how PRP integrates into multi-modality protocols.
Verifying Your Medellín Peptide Clinic on Day 1 (2026) — for the binary credential verification before booking.
GHK-Cu as a Post-Procedure Recovery Accelerator (2026) — for the GHK-Cu + exosomes + PRP three-way regenerative stack detail.
Peptide Therapy in Colombia: INVIMA Standards, Safety & Regulations (2026) — for regulatory framework background.

Who This Article Is NOT For

Patients seeking the cheapest possible PRP regardless of preparation quality.
Patients unwilling to ask the eight bedside questions.
Patients seeking PRP for indications where PRP alone is inadequate (end-stage radiographic disease, full-thickness tears, late-stage hair loss without viable follicles).
Patients seeking guarantees that defy biology.

The Bottom Line

PRP is not a single product. It is a category of products with order-of-magnitude variability in actual platelet concentration, leukocyte profile, preparation method, and clinical performance. Same word at the marketing level, different products at the clinical level.

The eight bedside questions take five minutes at a serious practice and produce immediate clarity at a practice that has not built the documentation infrastructure. Verification protects you and gets you the product you are paying for.

Ask which system. Ask single vs double spin. Ask LR vs LP and why. Ask the platelet concentration target. Ask for the CBC. Ask the yield. Ask about closed-system sterility. Ask about ACD-A. Five minutes. Five minutes determines whether you receive PRP or you receive an undocumented preparation labeled with the same word.

Schedule a Consultation

YouMedicine in El Poblado, Medellín administers PRP with full documentation: system used, spin protocol, leukocyte selection per indication, baseline platelet count, post-preparation concentration, yield percentage, and dose volume documented per administration. The same documentation standard applies whether the PRP is being administered for facial aesthetic, scalp microinjection, intra-articular, tendinopathy, or as a component of a combined regenerative protocol.

Email: wellness@youmedicine.co
WhatsApp: +57 324 576 1913
Location: El Poblado, Medellín, Colombia

In your first message, request:

The specific PRP system used at the clinic
The spin protocol and leukocyte selection appropriate for your indication
The platelet concentration target and yield documentation
The role PRP plays in your specific protocol — stand-alone session series, post-procedure adjunct, or component of a combined regenerative protocol